Validating survivin as a cancer therapeutic target

Nature Reviews Cancer

Volumn 3, Issue 1, 2003, Pages 46-54

  Altieri, Dario C ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INHIBITOR OF APOPTOSIS PROTEIN; PROTEIN BCL 2; SURVIVIN; BIRC5 PROTEIN, HUMAN; CYSTEINE PROTEINASE INHIBITOR; MICROTUBULE ASSOCIATED PROTEIN; TUMOR ANTIGEN; TUMOR PROTEIN;

CANCER THERAPY; CELLULAR DISTRIBUTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; STRUCTURE ACTIVITY RELATION; VALIDATION PROCESS; APOPTOSIS; DRUG EFFECT; HUMAN; NEOPLASM; PATHOLOGY; PHYSIOLOGY;

ANTIGENS, NEOPLASM; APOPTOSIS; CYSTEINE PROTEINASE INHIBITORS; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NEOPLASMS;

EID: 0037267333     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc968     Document Type: Review

References (126)

1. Kerr, J. F., Wyllie, A. H. & Currie, A. R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 26, 239-257 (1972).
2. Meier, P., Finch, A. & Evan, G. I. Apoptosis in development. Nature 407, 796-801 (2000).
3. Goyal, L. Cell death inhibition: keeping caspases in check. Cell 104, 805-808 (2001).
4. Krammer, P. H. CD95's deadly mission in the immune system. Nature 407, 789-795 (2000).
5. Wang, X. The expanding role of mitochondria in apoptosis. Genes Dev. 15, 2922-2933 (2001).
6. Li, P. et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91, 479-489 (1997).
7. Du, C., Fang, M., Li, Y., Li, L. & Wang, X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102, 33-42 (2000).
8. Cory, S. & Adams, J. M. The Bcl2 family: regulators of the cellular life-or-death switch. Nature Rev. Cancer 2, 647-656 (2002).
9. Zong, W. X., Lindsten, T., Ross, A. J., MacGregor, G. R. & Thompson, C. B. BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. Genes Dev. 15, 1481-1486 (2001).
10. Salvesen, G. S. & Duckett, C. S. IAP proteins: blocking the road to death's door. Nature Rev. Mol. Cell Biol. 3, 401-410 (2002).
11. Shi, Y. Mechanisms of caspase activation and inhibition during apoptosis. Mol. Cell 9, 459-470 (2002).
12. Birkey Reffey, S., Wurthner, J. U., Parks, W. T., Roberts, A. B. & Duckett, C. S. X-linked inhibitor of apoptosis protein functions as a cofactor in transforming growth factor-β signaling. J. Biol. Chem. 276, 26542-26549 (2001).
13. Sanna, M. G. et al. IAP suppression of apoptosis involves distinct mechanisms: the TAK1/JNK1 signaling cascade and caspase inhibition. Mol. Cell. Biol. 22, 1754-1766 (2002).
14. Uren, A. G. et al. Role for yeast inhibitor of apoptosis (IAP)-like proteins in cell division. Proc. Natl Acad. Sci. USA 96, 10170-10175 (1999).
15. Li, F., Flanary, P. L., Altieri, D. C. & Dohlman, H. G. Cell division regulation by BIR1, a member of the inhibitor of apoptosis family in yeast. J. Biol. Chem. 275, 6707-6711 (2000).
16. Morishita, J. et al. Bir1/Cut17 moving from chromosome to spindle upon the loss of cohesion is required for condensation, spindle elongation and repair. Genes Cells 6, 743-763 (2001).
17. Speliotes, E. K., Uren, A., Vaux, D. & Horvitz, H. R. The survivin-like C. elegans BIR-1 protein acts with the Aurora-like kinase AIR-2 to affect chromosomes and the spindle midzone. Mol. Cell 6, 211-223 (2000).
18. Fraser, A. G., James, C., Evan, G. I. & Hengartner, M. O. Caenorhabditis elegans inhibitor of apoptosis protein (IAP) homologue BIR-1 plays a conserved role in cytokinesis. Curr. Biol. 9, 292-301 (1999). First demonstration that ablation of an IAP gene in the nematode results in lethal defects of cell division without affecting programmed cell death.
19. Harlin, H., Reffey, S. B., Duckett, C. S., Lindsten, T. & Thompson, C. B. Characterization of XIAP-deficient mice. Mol. Cell. Biol. 21, 3604-3608 (2001).
20. Huang, H. et al. The inhibitor of apoptosis, cIAP2, functions as a ubiquitin-protein ligase and promotes in vitro monoubiquitination of caspases 3 and 7. J. Biol. Chem. 275, 26661-26664 (2000).
21. Yang, Y., Fang, S., Jensen, J. P. Weissman, A. M. & Ashwell, J. D. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science 288, 874-877 (2000).
22. Martin, S. J. Destabilizing influences in apoptosis: sowing the seeds of IAP destruction. Cell 109, 807-809 (2002).
23. Suzuki, Y., Nakabayashi, Y. & Takahashi, R. Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death. Proc. Natl Acad. Sci. USA 98, 8662-8667 (2001).
24. Ambrosini, G., Adida, C. & Altieri, D. C. A novel antiapoptosis gene, survivin, expressed in cancer and lymphoma. Nature Med. 3, 917-921 (1997).
25. Li, F. et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396, 580-584 (1998). Demonstration that survivin interfaces between the microtubule control of cell division and the preservation of an anti-apoptotic environment in dividing cells.
26. Li, F. & Altieri, D. C. The cancer antiapoptosis mouse survivin gene: characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression. Cancer Res. 59, 3143-3151 (1999).
27. Mahotka, C., Wenzel, M., Springer, E., Gabbert, H. E. & Gerharz, C. D. Survivin-ΔEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res. 59, 6097-6102 (1999). Identification of two alternatively spliced forms of survivin that are potentially divergent from the wild-type protein for subcellular localization and the ability to counteract apoptosis.
28. Rodriguez, J. A., Span, S. W., Ferreira, C. G., Kruyt, F. A. & Giaccone, G. CRM1-mediated nuclear export determines the cytoplasmic localization of the antiapoptotic protein Survivin. Exp. Cell Res. 275, 44-53 (2002).
29. Wang, H. W., Sharp, T. V., Koumi, A., Koentges, G. & Boshoff, C. Characterization of an anti-apoptotic glycoprotein encoded by Kaposi's sarcoma-associated herpesvirus which resembles a spliced variant of human survivin. EMBO J. 21, 2602-2615 (2002). A new twist in the survivin cytoprotection pathway: localization of a herpes simplex virus homologue of alternatively spliced survivin-AEx3 to mitochondria and physical interaction with caspase-3.
30. Verdecia, M. A. et al. Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement. Nature Struct. Biol. 7, 602-608 (2000).
31. Chantalat, L. et al. Crystal structure of human survivin reveals a bow tie-shaped dimer with two unusual alpha-helical extensions. Mol. Cell 6, 183-189 (2000).
32. Muchmore, S. W. et al. Crystal structure and mutagenic analysis of the inhibitor-of-apoptosis protein survivin. Mol. Cell 6, 173-182 (2000).
33. Badie, C., Itzhaki, J. E., Sullivan, M. J., Carpenter, A. J. & Porter, A. C. Repression of CDK1 and other genes with CDE and CHR promoter elements during DNA damage-induced G(2)/M arrest in human cells. Mol. Cell. Biol. 20, 2358-2366 (2000).
34. Kobayashi, K., Hatano, M., Otaki, M., Ogasawara, T. & Tokuhisa, T. Expression of a murine homologue of the inhibitor of apoptosis protein is related to cell proliferation. Proc. Natl Acad. Sci. USA 96, 1457-1462 (1999).
35. Li, F. & Altieri, D. C. Transcriptional analysis of human survivin gene expression. Biochem. J. 344, 305-311 (1999).
36. Zhao, J., Tenev, T., Martins, L. M., Downward, J. & Lemoine, N. R. The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. J. Cell Sci. 113, 4363-4371 (2000).
37. O'Connor, D. S., Wall, N. R., Porter, A. C. & Altieri, D. C. A p34(cdc2) survival checkpoint in cancer. Cancer Cell 2, 43-54 (2002). Rational targeting of survivin to maximize the antitumour effect of taxane-based chemotherapy in cancer treatment.
38. Li, F. et al. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nature Cell Biol. 1, 461-466 (1999).
39. Jiang, X. et al. Participation of Survivin in mitotic and apoptotic activities of normal and tumor-derived cells. J. Cell Biochem. 83, 342-354 (2001).
40. Skoufias, D. A., Mollinari, C., Lacroix, F. B. & Margolis, R. L. Human survivin is a kinetochore-associated passenger protein. J. Cell Biol. 151, 1575-1582 (2000).
41. Fortugno, P. et al. Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J. Cell Sci. 115, 575-585 (2002). Reconciles earlier discrepant findings on the subcellular localization of survivin to multiple compartments of the mitotic apparatus.
42. Wheatley, S. P., Carvalho, A., Vagnarelli, P. & Earnshaw, W. C. INCENP is required for proper targeting of Survivin to the centromeres and the anaphase spindle during mitosis. Curr. Biol. 11, 886-890 (2001).
43. Uren, A. G. et al. Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr. Biol. 10, 1319-1328 (2000).
44. Fukuda, S. & Pelus, L. M. Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34(+) cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis. Blood 98, 2091-2100 (2001).
45. Fukuda, S., Foster, R. G., Porter, S. B. & Pelus, L. M. The antiapoptosis protein survivin is associated with cell cycle entry of normal cord blood CD34(+) cells and modulates cell cycle and proliferation of mouse hematopoietic progenitor cells. Blood 100, 2463-2471 (2002). Demonstration that survivin gene expression can occur independently of mitotic progression in interphase bone-marrow progenitor cells.
46. Mahboubi, K. et al. Interleukin-11 up-regulates survivin expression in endothelial cells through a signal transducer and activator of transcription-3 pathway. Lab. Invest. 81, 327-334 (2001).
47. Papapetropoulos, A. et al. Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J. Biol. Chem. 275, 9102-9105 (2000).
48. Aoki, Y., Feldman, G. M. & Tosato, G. Inhibition of STAT3 signaling induces apoptosis and decreases Survivin expression in primary effusion lymphoma. Blood 3 Oct 2002 [epub ahead of print].
49. Silke, J. & Vaux, D. L. Two kinds of BIR-containing protein-inhibitors of apoptosis, or required for mitosis. J. Cell Sci. 114, 1821-1827 (2001).
50. Adams, R. R., Carmena, M. & Earnshaw, W. C. Chromosomal passengers and the (aurora) ABCs of mitosis. Trends Cell Biol. 11, 49-54 (2001).
51. Tamm, I. et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 58, 5315-5320 (1998).
52. Suzuki, A. et al. Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death. Oncogene 19, 1346-1353 (2000).
53. Islam, A. et al. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 19, 617-623 (2000).
54. Kasof, G. M. & Gomes, B. C. Livin, a novel inhibitor-of-apoptosis (IAP) family member. J. Biol. Chem. 276, 3238-3246 (2000).
55. Mirza, A. et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 21, 2613-2622 (2002).
56. Hoffman, W. H., Biade, S., Zilfou, J. T., Chen, J. & Murphy, M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J. Biol. Chem. 277, 3247-3257 (2001). A potential molecular basis for the widespread differential expression of survivin in embryologically disparate tumours following loss of wild-type p53.
57. Zaffaroni, N. et al. Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol. Life Sci. 59, 1406-1412 (2002).
58. Grossman, D. et al. Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53. J. Clin. Invest. 108, 991-999 (2001). A functional link between survivin and loss of p53 in ablating apoptosis in a transgenic mouse model.
59. Conway, E. M. et al. Deficiency of survivin in transgenic mice exacerbates Fas-induced apoptosis via mitochondrial pathways. Gastroenterology 123, 619-631 (2002).
60. Hikita, S. et al. Overexpression of TIAP/m-survivin in thymocytes enhances cell proliferation. Mol. Immunol. 39, 289-298 (2002).
61. Ambrosini, G., Adida, C., Sirugo, G. & Altieri, D. C. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J. Biol. Chem. 273, 11177-11182 (1998).
62. Grossman, D., McNiff, J. M., Li, F. & Altieri, D. C. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. Invest. Dermatol. 113, 1076-1081 (1999).
63. Chen, J. et al. Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage-independent growth. Neoplasia 2, 235-241 (2000).
64. Olie, R. A. et al. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res. 60, 2805-2809 (2000).
65. Shankar, S. L. et al. Survivin inhibition induces human neural tumor cell death through caspase-independent and -dependent pathways. J. Neurochem. 79, 426-436 (2001).
66. Kanwar, J. R., Shen, W. P., Kanwar, R. K., Berg, R. W. & Krissansen, G. W. Effects of survivin antagonists on growth of established tumors and b7-1 immunogene therapy. J. Natl Cancer Inst. 93, 1541-1552 (2001). Establishes proof of concept that targeting survivin in vivo cooperates with anticancer regimens and facilitates tumour eradication.
67. Pennati, M. et al. Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis. J. Clin. Invest. 109, 285-286 (2002).
68. Zhou, M. et al. DNA damage induces a novel p53-survivin signaling pathway regulating cell cycle and apoptosis in acute lymphoblastic leukemia cells. J. Pharmacol. Exp. Ther. 303, 124-131 (2002).
69. Jones, G., Jones, D., Zhou, L., Steller, H. & Chu, Y. Deterin, a new inhibitor of apoptosis from Drosophila melanogaster. J. Biol. Chem. 275, 22157-22165 (2000).
70. Conway, E. M. et al. Three differentially expressed survivin cDNA variants encode proteins with distinct antiapoptotic functions. Blood 95, 1435-1442 (2000).
71. Shin, S. et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 40, 1117-1123 (2001).
72. cdc2 phosphorylation of survivin. Proc. Natl Acad. Sci. USA 97, 13103-13107 (2000).
73. Mesri, M., Wall, N. R., Li, J., Kim, R. W. & Altieri, D. C. Cancer gene therapy using a survivin mutant adenovirus. J. Clin. Invest. 108, 981-990 (2001).
74. Kallio, M. J., Nieminen, M. & Eriksson, J. E. Human inhibitor of apoptosis protein (IAP) survivin participates in regulation of chromosome segregation and mitotic exit. FASEB J. 15, 2721-2723 (2001).
75. Bolton, M. A. et al. Aurora B kinase exists in a complex with survivin and INCENP and its kinase activity is stimulated by survivin binding and phosphorylation. Mol. Biol. Cell 13, 3064-3077 (2002). A survivin homologue in Xenopus laevis controls the enzymatic activity of Aurora kinase, a multifunctional regulator of mitosis.
76. Giodini, A. et al. Regulation of microtubule stability and mitotic progression by survivin. Cancer Res. 62, 2462-2467 (2002).
77. Tran, J. et al. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc. Natl Acad. Sci. USA 99, 4349-4354 (2002). Demonstration that survivin can reduce the effectiveness of anti-angiogenic therapy in cancer treatment.
78. Adida, C. et al. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am. J. Pathol. 152, 43-49 (1998).
79. Carter, B. Z., Milella, M., Altieri, D. C. & Andreeff, M. Cytokine-regulated expression of survivin in myeloid leukemia. Blood 97, 2784-2790 (2001).
80. Gianani, R. et al. Expression of survivin in normal, hyperplastic, and neoplastic colonic mucosa. Hum. Pathol. 32, 119-125 (2001).
81. Zhang, T. et al. Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res. 61, 8664-8667 (2001).
82. Monzo, M. et al. A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J. Clin. Oncol. 17, 2100-2104 (1999).
83. Tanaka, K. et al. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin. Cancer Res. 6, 127-134 (2000).
84. Kawasaki, H. et al. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 58, 5071-5074 (1998).
85. Lu, C. D., Altieri, D. C. & Tanigawa, N. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res. 58, 1808-1812 (1998).
86. Kato, J. et al. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int. J. Cancer 95, 92-95 (2001).
87. Satoh, K. et al. Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer 92, 271-278 (2001).
88. Ikeguchi, M., Ueta, T., Yamane, Y., Hirooka, Y. & Kaibara, N. Inducible nitric oxide synthase and survivin messenger RNA expression in hepatocellular carcinoma. Clin. Cancer Res. 8, 3131-3136 (2002).
89. Saitoh, Y., Yaginuma, Y. & Ishikawa, M. Analysis of Bcl-2, Bax and Survivin genes in uterine cancer. Int. J. Oncol. 15, 137-141 (1999).
90. Yoshida, H., Ishiko, O., Sumi, T., Matsumoto, Y. & Ogita, S. Survivin, Bcl-2 and matrix metalloproteinase-2 enhance progression of clear cell- and serous-type ovanan carcinomas. Int. J. Oncol. 19, 537-542 (2001).
91. Garcia, J. F. et al. Hodgkin's and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue-microarrays. Blood 12 Sept 2002 [epub ahead of print].
92. Adida, C. et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 96, 1921-1925 (2000).
93. Kuttler, F. et al. Relationship between expression of genes involved in cell cycle control and apoptosis in diffuse large B cell lymphoma: a preferential survivin-cyclin B link. Leukemia 16, 726-735 (2002).
94. Adida, C. et al. Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br. J. Haematol. 111, 196-203 (2000).
95. Kamihira, S. et al. Aberrant expression of caspase cascade regulatory genes in adult T-cell leukaemia: survivin is an important determinant for prognosis. Br. J. Haematol. 114, 63-69 (2001).
96. Adida, C., Berrebi, D., Peuchmaur, M., Reyes-Mugica, M. & Altieri, D. C. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 351, 882-883 (1998).
97. Koch, C. A. et al. Survivin: a novel neuroendocrine marker for pheochromocytoma. Eur. J. Endocrinol. 146, 381-388 (2002).
98. Wurl, P. et al. Co-expression of survivin and TERT and risk of tumour-related death in patients with soft-tissue sarcoma. Lancet 359, 943-945 (2002).
99. Chakravarti, A. et al. Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J. Clin. Oncol. 20, 1063-1068 (2002).
100. Hirohashi, Y. et al. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin. Cancer Res. 8, 1731-1739 (2002).
101. Bao, R. et al. Activation of cancer-specific gene expression by the survivin promoter. J. Natl Cancer Inst. 94, 522-528 (2002). Strong evidence that the differential expression of survivin in cancer versus normal tissues is largely controlled at the level of gene transcription.
102. Hattori, M., Sakamoto, H., Satoh, K. & Yamamoto, T. DNA demethylase is expressed in ovarian cancers and the expression correlates with demethylation of CpG sites in the promoter region of c-erbB-2 and survivin genes. Cancer Lett. 169, 155-164 (2001).
103. Kappler, M. et al. Increased survivin transcript levels: an independent negative predictor of survival in soft tissue sarcoma patients. Int. J. Cancer 95, 360-363 (2001).
104. Sarela, A. I., Macadam, R. C., Farmery, S. M., Markham, A. F. & Guillou, P. J. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 46, 645-650 (2000).
105. Ikeguchi, M. & Kaibara, N. Survivin messenger RNA expression is a good prognostic biomarker for oesophageal carcinoma. Br. J. Cancer 87, 883-887 (2002).
106. Swana, H. S., Grossman, D., Anthony, J. N., Weiss, R. M. & Altieri, D. C. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N. Engl. J. Med. 341, 452-453 (1999).
107. Andersen, M. H. & thor, S. P. Survivin: a universal tumor antigen. Histol. Histopathol. 17, 669-675 (2002).
108. Rohayem, J. et al. Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res. 60, 1815-1817 (2000).
109. Yagihashi, A. et al. Detection of anti-survivin antibody in gastrointestinal cancer patients. Clin. Chem. 47, 1729-1731 (2001).
110. + T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res. 60, 4845-4849 (2000). First demonstration that survivin can elicit a tumour-specific immune response of potential therapeutic significance for cancer vaccination strategies.
111. Andersen, M. H., Pedersen, L. O., Becker, J. C. & Straten, P. T. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res. 61, 869-872 (2001).
112. Yamamoto, T., Manome, Y., Nakamura, M. & Tanigawa, N. Downregulation of survivin expression by induction of the effector cell protease receptor-1 reduces tumor growth potential and results in an increased sensitivity to anticancer agents in human colon cancer. Eur. J. Cancer 38, 2316-2324 (2002).
113. Grossman, D., Kim, P. J., Schechner, J. S. & Altieri, D. C. Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc. Natl Acad. Sci. USA 98, 635-640 (2001).
114. Sausville, E. A. Complexities in the development of cyclin-dependent kinase inhibitor drugs. Trends Mol. Med. 8, S32-S37 (2002).
115. Schwartz, G. K. et al. Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J. Clin. Oncol. 20, 2157-2170 (2002).
116. Tao, W. et al. Human homologue of the Drosophila melanogaster lats tumour suppressor modulates CDC2 activity. Nature Genet. 21, 177-181 (1999).
117. Theile, M. et al. A defined chromosome 6q fragment (at D6S310) harbors a putative tumor suppressor gene for breast cancer. Oncogene 13, 677-685 (1996).
118. Xia, H. et al. LATS1 tumor suppressor regulates G2/M transition and apoptosis. Oncogene 21, 1233-1241 (2002).
119. Itzhaki, J. E., Gilbert, C. S. & Porter, A. C. G. Construction by gene targeting in human cells of a 'conditional' CDC2 mutant that rereplicates its DNA. Nature Genet. 15, 258-265 (1997).
120. Ongkeko, W., Ferguson, D. J. P., Harris, A. L. & Norbury, C. Inactivation of Cdc2 increases the level of apoptosis induced by DNA damage. J. Cell Sci. 108, 2897-2904 (1995).
121. Gray N. S. et al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 281, 533-538 (1998).
122. Cdc2 kinase. Mol. Cell 2, 581-591 (1998).
123. O'Connor, D. S. et al. Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am. J. Pathol. 156, 393-398 (2000).
124. Tran, J. et al. Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem. Biophys. Res. Commun. 264, 781-788 (1999).
125. Mesri, M. et al. Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting. Am. J. Pathol. 158, 1757-1765 (2001).
126. Nicholson, D. W. From bench to clinic with apoptosis-based therapeutic agents. Nature 407, 810-816 (2000).